Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trialFriedrich Koehler, Karl Stangl, Kerstin Koehler et al.|The Lancet|2018Cited by 734
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceAndrew A. House, Stefan Störk, Michael Cheung et al.|Kidney International|2019Cited by 435
Rationale and Design of the DIGIT-HF Trial (DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure): A Randomized, Double-Blind, Placebo-Controlled StudyUdo Bavendiek, Johann Bauersachs, Dominik Berliner et al.|European Journal of Heart Failure|2019Cited by 82
Digitoxin in Patients with Heart Failure and Reduced Ejection FractionUdo Bavendiek, Johann Bauersachs, Anika Großhennig et al.|New England Journal of Medicine|2025Cited by 65
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trialFriedrich Koehler, Stefan D. Anker, Sandra Prescher et al.|The Lancet Digital Health|2019Cited by 61